Health & Research Goals
GHK-Cu (Copper Peptide Complex)
GHK-Cu (Complejo Peptídico de Cobre)
GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper) is a naturally occurring copper peptide complex consisting of three amino acids (Gly-Hi…
Primary Description
GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper) is a naturally occurring copper peptide complex consisting of three amino acids (Gly-His-Lys) bound to a copper ion (Cu²⁺). First discovered in human plasma, it is one of the most genomically active peptides ever studied, regulating 31.2% of the entire human genome (4,200 genes: 2,687 stimulated, 1,513 suppressed). GHK-Cu is released from collagen during tissue damage, acting as a natural injury sensor and repair signal. Plasma levels decline from 200 ng/mL at age 20 to 80 ng/mL at age 60 (a 60% decline), potentially explaining reduced healing capacity with aging. In head-to-head clinical studies, GHK-Cu outperforms Matrixyl 3000 (31.6% better wrinkle reduction), Vitamin C (40% more women showed collagen improvement), and Retinoic Acid (75% more women showed collagen improvement).
Key Benefits
- Wound healing
- Collagen synthesis
- Anti-aging
Stable as lyophilized powder at -20°C. Topical formulations should be stored away from light and heat. Reconstituted injectable solutions stable at 2–8°C for up to 30 days. The Cu²⁺ ion is essential for biological activity — avoid chelating agents.
Demonstrated Effects
- Regulates 31.2% of the human genome (4,200 genes) — unprecedented genomic activity
- Clinically superior collagen synthesis vs Matrixyl 3000, Vitamin C, and Retinoic Acid
- Accelerated wound healing and tissue repair via angiogenesis and fibroblast stimulation
- Anti-aging gene profile: activates DNA repair, antioxidant defense, and stem cell genes
- Anti-inflammatory: suppresses IL-6, TNF-alpha, and MMP genes
- 408 neuron-specific genes upregulated — neuroprotective and cognitive health effects
- 12.5-fold increase in fibroblast viability when combined with LED light therapy
- Stem cell pluripotency gene activation (Oct4, Nanog)
- Copper ion delivery activating lysyl oxidase, SOD, and cytochrome c oxidase
- Biphasic angiogenesis regulation — stimulates in wound healing, suppresses in pathological contexts
Proposed Mechanisms of Action
1. Genome-Wide Gene Regulation (31.2% of Human Genome)
GHK-Cu affects 4,200 genes: 2,687 upregulated (collagen synthesis, antioxidant defense, DNA repair, stem cell genes, 408 neuron genes) and 1,513 downregulated (pro-inflammatory cytokines, MMP collagen breakdown, fibrosis genes, oxidative stress genes). Some genes increased by up to 1,294%.
2. Copper Ion Delivery and Metalloprotein Activation
The Cu²⁺ component activates lysyl oxidase (collagen/elastin cross-linking), copper-zinc SOD (antioxidant), cytochrome c oxidase (mitochondrial ATP production), and modulates tyrosinase (melanin regulation).
3. Biphasic Angiogenesis Regulation
GHK-Cu stimulates therapeutic angiogenesis in wound healing contexts via VEGF and FGF gene upregulation, while also demonstrating anti-angiogenic effects in pathological contexts — a biphasic response dependent on tissue microenvironment.
4. Collagen Synthesis and Anti-Fibrotic Effects
Stimulates COL1A1 and COL3A1 (collagen production) while suppressing TGF-β1 fibrosis signaling and MMP collagen breakdown genes — net effect is improved collagen quality without excess scarring.
5. Stem Cell Activation
Activates stem cell pluripotency genes including Oct4 and Nanog, potentially explaining systemic tissue regeneration capacity restoration observed in aging models.
6. Anti-Inflammatory Gene Suppression
Downregulates IL-6, TNF-alpha, IL-1beta, and other pro-inflammatory cytokine genes, providing sustained anti-inflammatory gene expression changes.
Research Evidence & Clinical Data
Investigated Applications
Skin Rejuvenation and Anti-Aging
Anecdotal: HighThe most established application with head-to-head clinical data against leading cosmetic treatments. GHK-Cu demonstrates superior wrinkle reduction, collagen stimulation, and skin elasticity improvement compared to Matrixyl 3000, Vitamin C, and Retinoic Acid.
Preclinical basis: Stimulates COL1A1 and COL3A1 collagen genes; suppresses MMP-1 and MMP-2 collagen breakdown genes. Clinical RCTs demonstrate superior collagen improvement vs gold-standard comparators.
Wound Healing and Tissue Repair
Anecdotal: HighExtensive preclinical and some clinical evidence supports GHK-Cu for accelerated wound closure, angiogenesis, and reduced scarring. Diabetic wound models show particularly strong results.
Preclinical basis: Hong SS et al. (2016): GHK-Cu promotes wound healing by stimulating angiogenesis and collagen synthesis in diabetic rats. VEGF and FGF gene upregulation drives angiogenesis.
Anti-Aging and Longevity
Anecdotal: ModerateThe genomic data showing activation of DNA repair genes, antioxidant defense, stem cell pluripotency genes, and suppression of oxidative stress genes positions GHK-Cu as one of the most biologically compelling longevity peptides in the research community.
Preclinical basis: Pickart L et al. (2012): GHK-Cu regulates 31.2% of human genome with anti-aging gene profile; activates stem cell pluripotency and DNA repair genes; suppresses cancer-associated and oxidative stress genes.
Neuroprotection
Anecdotal: Emerging408 neuron-specific genes upregulated by GHK-Cu, including BDNF, NGF, and synaptic proteins, suggest neuroprotective potential for cognitive aging, neuroinflammation, and neurodegenerative conditions.
Preclinical basis: Pickart L et al. (2012): 408 neuron-specific genes upregulated in GHK-Cu genomic study, including genes involved in BDNF signaling, synaptic function, and brain aging protection.
Scientific References
- 1.
- 2.The potential of GHK as an anti-aging peptideAging Pathobiol Ther2020
- 3.Intranasal GHK peptide enhances resilience to cognitive decline in aging micebioRxiv (preprint)2023
Safety Profile
Common Side Effects
- Injection site redness or mild swelling
- Temporary skin flushing with topical use
- Mild headaches (rare, transient)
- Metallic taste with oral supplementation
- Minimal
Contraindications
- Active cancer or cancer within past 5 years (biphasic angiogenesis; cell proliferation stimulation)
- Wilson's Disease or copper metabolism disorders (copper ion delivery)
- Pregnancy or breastfeeding (systemic use)
- Diabetic retinopathy or macular degeneration (angiogenic effects)
- Personal or family history of keloid scarring (collagen stimulation)
- Copper sensitivity
Legal & Regulatory Status
Not FDA-approved for therapeutic use. Widely available as cosmetic ingredient in topical formulations (legal for cosmetic use). Injectable/systemic form classified as research chemical. WADA prohibited (S0). No controlled substance scheduling in major jurisdictions.
No aprobado por FDA para uso terapéutico. Ampliamente disponible como ingrediente cosmético en formulaciones tópicas (legal para uso cosmético). Forma inyectable/sistémica clasificada como químico de investigación. Prohibido WADA (S0). Sin clasificación de sustancia controlada en jurisdicciones principales.
Research Protocols
Dosing Protocols
Routes of Administration
subcutaneous
topical
oral
Reconstitution Guide
Pharmacokinetics
| Half-Life | Short plasma half-life (~30 minutes after IV/sub-Q); effects are genomic and sustained beyond peptide clearance |
Monitoring & Risk Management
Ongoing Monitoring Steps
- Skin and wound healing response — track improvement weekly
- Injection site assessment at each injection
- Serum copper levels if using long-term at higher systemic doses
- Monitor any existing skin lesions or moles for changes
- Cognitive and energy markers for anti-aging longevity protocols
Critical Warning Signs
- New or changing skin lesions — stop and evaluate
- Signs of copper toxicity (nausea, abdominal pain, jaundice) with high-dose oral use
- Rapid or excessive scar tissue formation at injection sites
- Severe allergic reaction
- Visual changes if using with any retinal condition
Featured in Stacking Protocols
Community-researched combinations involving this compound